Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort-Reference-Cited by-同舟云学术

Clinical Evaluation of the XDR-LFC Assay for the Molecular Detection of Isoniazid, Rifampin, Fluoroquinolone, Kanamycin, Capreomycin, and Amikacin Drug Resistance in a Prospective Cohort

Published:2023-03-23 Issue:3 Volume:61 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Syed Rehan R.¹^ORCID,Catanzaro Donald G.²^ORCID,Colman Rebecca E.¹^ORCID,Cooney Christopher G.³,Linger Yvonne³,Kukhtin Alexander V.³,Holmberg Rebecca C.³,Norville Ryan³,Crudu Valeriu⁴,Ciobanu Nelly⁴,Codreanu Alexandru⁴,Seifert Marva¹^ORCID,Hillery Naomi⁵,Chiles Peter¹,Catanzaro Antonino¹,Rodwell Timothy C.¹

Affiliation:

1. Department of Medicine, University of California, San Diego, La Jolla, California, USA

2. Department of Biological Sciences, University of Arkansas, Fayetteville, Arkansas, USA

3. Akonni Biosystems, Inc., Frederick, Maryland, USA

4. Phthisiopneumology Institute, Chișinău, Republic of Moldova

5. Herbert Wertheim School of Public Health and Human Longevity Science, University of California, San Diego, La Jolla, California, USA

Abstract

While the goal of universal drug susceptibility testing has been a key component of the WHO End TB Strategy, in practice, this remains inaccessible to many. Rapid molecular tests for tuberculosis (TB) and antituberculosis drug resistance could significantly improve access to testing.

Funder

HHS | NIH | National Institute of Allergy and Infectious Diseases

HHS | NIH | National Institute of Biomedical Imaging and Bioengineering

HHS | NIH | National Institute of General Medical Sciences

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/jcm.01478-22

Reference35 articles.

1. World Health Organization. 2022. Global tuberculosis report 2022. World Health Organization, Geneva, Switzerland.

2. World Health Organization. 2015. The End TB Strategy. World Health Organization, Geneva, Switzerland.

3. World Health Organization. 2021. WHO operational handbook on tuberculosis. Module 3: diagnosis—rapid diagnostics for tuberculosis detection, 2021 update. World Health Organization, Geneva, Switzerland.

4. World Health Organization. 2021. WHO announces updated definitions of extensively drug-resistant tuberculosis. World Health Organization, Geneva, Switzerland.

5. World Health Organization. 2021. Fact sheet: tuberculosis. World Health Organization, Geneva, Switzerland. https://www.who.int/news-room/fact-sheets/detail/tuberculosis.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Evaluation of MeltPro Assay in Identification of Second-Line Injectable Drug Resistance in Multidrug-Resistant Tuberculosis Isolates;Infection and Drug Resistance;2024-05

2. Identification of the Seaweed Metabolites as Potential Anti-tubercular Agents Against Human Pantothenate synthetase: An In Silico Approach;Current Microbiology;2023-08-14

3. Whole-Genome Sequencing to Predict Mycobacterium tuberculosis Drug Resistance: A Retrospective Observational Study in Eastern China;Antibiotics;2023-07-31